Core Viewpoint - Meihui Biotechnology (Shanghai) Co., Ltd. has been fined 30,000 yuan for false advertising of its "Taikong 30" product during a live-streaming event, as determined by the Shanghai Chongming District Market Supervision Administration [1][5]. Group 1: Company Overview - Meihui Biotechnology is the exclusive e-commerce distributor for the "Junxiaobao" series of products from Shanghai Junxiaobao Health Technology Co., Ltd. [3] - The company is part of the Shanghai Chenguan Health Technology Group, which was founded by Tu Zuitao in 2002 and has since expanded into the probiotics market with the launch of Junxiaobao in 2021 [11]. Group 2: Product and Marketing Strategy - The "Taikong 30" product was marketed as a powerful guardian for women's health, claiming to improve private area conditions within 10 days and alleviate various gynecological issues [4][5]. - Junxiaobao's marketing strategy heavily relies on celebrity endorsements and collaborations with top live-streaming hosts, achieving significant sales figures during promotional events, such as over 50.6 million yuan in GMV from a collaboration with the Guo Yue couple [15]. Group 3: Regulatory Action and Implications - The Shanghai market regulator found that the "Taikong 30" product is merely a regular food item without any therapeutic claims, leading to a violation of the Anti-Unfair Competition Law [5]. - The incident serves as a warning to the industry about the risks of relying solely on traffic-driven marketing without adhering to product integrity and compliance [15].

Core Viewpoint - The article highlights a case of false advertising involving Meihui Biotechnology (Shanghai) Co., Ltd., which was fined for misleading claims about its product "TaiKong 30" during a live-streaming event [1][10]. Group 1: Company Overview - Meihui Biotechnology is the exclusive e-commerce distributor of the "Junxiaobao" product line, which includes the controversial "TaiKong 30" [3]. - The "Junxiaobao" brand is operated by Shanghai Junxiaobao Health Technology Co., Ltd., a subsidiary of Shanghai Chenguan Health Technology Group, founded by Tu Zuitao in 2002 [18][19]. Group 2: Product and Marketing Strategy - The "TaiKong 30" product was marketed as a powerful solution for women's health, claiming to improve private area conditions within 10 days and alleviate various gynecological issues [6][9]. - The brand has utilized a robust marketing strategy involving celebrity endorsements and collaborations with top live-streaming hosts, achieving significant sales figures, such as over 50.6 million yuan in GMV from a collaboration with the Guo Yue couple [27][28]. Group 3: Regulatory Actions and Consequences - The Shanghai market supervision authority initiated an investigation into Meihui Biotechnology for false advertising, leading to a fine of 30,000 yuan [1][11]. - The investigation revealed that the "TaiKong 30" product is merely a regular food item without any therapeutic claims, contradicting the promotional statements made during live streams [9][10]. Group 4: Market Performance and Implications - Despite the regulatory issues, Junxiaobao reported a remarkable 406.51% year-on-year increase in online sales during the 2024 618 shopping festival, ranking fourth in the health supplement sector [30]. - The incident serves as a cautionary tale for the industry, emphasizing the risks of prioritizing sales over compliance and product integrity, which could lead to regulatory scrutiny and market exclusion [33].